Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.

Chung HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, Kao S, Miller WH Jr, Delord JP, Gao B, Planchard D, Gottfried M, Zer A, Jalal SI, Penel N, Mehnert JM, Matos I, Bennouna J, Kim DW, Xu L, Krishnan S, Norwood K, Ott PA

Open source

DOI: 10.1016/j.jtho.2019.12.109
Published: 2020 Apr
Container: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2019.12.109,
  title = {Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.},
  author = {Chung HC and Piha-Paul SA and Lopez-Martin J and Schellens JHM and Kao S and Miller WH Jr and Delord JP and Gao B and Planchard D and Gottfried M and Zer A and Jalal SI and Penel N and Mehnert JM and Matos I and Bennouna J and Kim DW and Xu L and Krishnan S and Norwood K and Ott PA},
  year = {2020},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2019.12.109},
  url = {https://doi.org/10.1016/j.jtho.2019.12.109}
}

RIS

TY  - JOUR
TI  - Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
AU  - Chung HC
AU  - Piha-Paul SA
AU  - Lopez-Martin J
AU  - Schellens JHM
AU  - Kao S
AU  - Miller WH Jr
AU  - Delord JP
AU  - Gao B
AU  - Planchard D
AU  - Gottfried M
AU  - Zer A
AU  - Jalal SI
AU  - Penel N
AU  - Mehnert JM
AU  - Matos I
AU  - Bennouna J
AU  - Kim DW
AU  - Xu L
AU  - Krishnan S
AU  - Norwood K
AU  - Ott PA
PY  - 2020
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2019.12.109
UR  - https://doi.org/10.1016/j.jtho.2019.12.109
ER  -

APA

HC, C., SA, P., J, L., JHM, S., S, K., Jr, M. W., JP, D., B, G., D, P., M, G., A, Z., SI, J., N, P., JM, M., I, M., J, B., DW, K., L, X., S, K., K, N., & PA, O. (2020). Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2019.12.109

Source records

pubmed · retrieved 2026-09-26T20:36:59.283Z